Jane Street
TBPH icon

Jane Street’s Theravance Biopharma TBPH Stock Holding History

Jane Street’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$226K Buy
+13,900
New +$246K ﹤0.01% 9871
2025
Q4 		– Sell
-101,100
Closed -$1.48M – 12357
2025
Q3 		$1.48M Buy
+101,100
New +$1.28M ﹤0.01% 5497
2023
Q2 		– Sell
-13,200
Closed -$143K – 9551
2023
Q1 		$143K Sell
13,200
-4,000
-23% -$42.3K ﹤0.01% 8037
2022
Q4 		$193K Sell
17,200
-3,200
-16% -$33.6K ﹤0.01% 7693
2022
Q3 		$207K Sell
20,400
-11,600
-36% -$109K ﹤0.01% 8128
2022
Q2 		$290K Sell
32,000
-322,100
-91% -$2.97M ﹤0.01% 7665
2022
Q1 		$3.38M Buy
+354,100
New +$3.47M ﹤0.01% 3713

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street's TBPH Position: Q1 2026 in Review

Jane Street sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 55,831 shares — an estimated $988K sold.

Jane Street first reported a position in TBPH in Q1 2016 and held it in 23 quarters. The position peaked at $25.6M in Q2 2020. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Jane Street reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 55,831 Theravance Biopharma shares in Q1 2026, an estimated $988K.
  • Jane Street first reported a position in Theravance Biopharma in Q1 2016 and held it in 23 quarters.
  • Jane Street's Theravance Biopharma position peaked at $25.6M in Q2 2020.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.